Careium (CARE) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 May, 2026Executive summary
Net sales grew 5.9% year-over-year to SEK 219.6m, with organic sales up 10.9% adjusted for currency, reflecting growth in all markets.
Product sales rose 18.1% to SEK 55.6m, and service sales increased to SEK 163.9m, with service sales up 2.3% year-over-year.
Profit for the period increased to SEK 8.4m, with EPS at SEK 0.31.
Operating profit (EBIT) declined to SEK 12.5m due to investments in product development, business integration, and onboarding a major Norwegian customer.
Recurring revenues and long-term contracts provide stability and a solid foundation for future growth.
Financial highlights
EBITDA decreased 10.4% to SEK 30.1m, with an EBITDA margin of 13.7%.
EBIT fell 25.1% to SEK 12.5m, with an EBIT margin of 5.7%.
Gross margin was 43.2%, slightly down from 44.5% year-over-year.
Free cash flow was negative at SEK -14.0m, impacted by working capital normalization.
Cash and cash equivalents increased to SEK 37.9m, while net debt decreased to SEK 169.9m.
Outlook and guidance
Margin pressure from ongoing investments and onboarding of a large customer in Norway expected to continue into Q2.
Continued benefit anticipated from the transition to digital infrastructure in the UK.
Focus remains on structural improvement initiatives and onboarding of new CEO.
Demographic trends and technology transformation in care sector support long-term growth prospects.
No financial guidance provided.
Latest events from Careium
- Q4 2025 delivered modest sales growth, lower EBIT, and stronger cash flow amid margin pressure.CARE
Q4 202516 Feb 2026 - Aging demographics fuel growth in care tech, with innovation and recurring revenue driving strategy.CARE
ABGSC Investor Days12 Jan 2026 - Q3 2025 delivered 6% sales growth, higher margins, and strong product sales despite one-off costs.CARE
Q3 202524 Oct 2025 - Sales fell but gross margin and cash flow improved; H2 growth expected from new contracts.CARE
Q2 202511 Jul 2025 - Sales dropped 7.2%, but strong margins and new platforms support growth targets.CARE
Q3 202413 Jun 2025 - Q2 sales and EBIT surged, driven by EU market gains despite UK/Nordic delays.CARE
Q2 202413 Jun 2025 - Gross margin rose to 44.5% despite lower sales, with growth outside Sweden and strong 2025 outlook.CARE
Q1 20255 Jun 2025 - Strong sales and profit growth, with 2025 set for further expansion and innovation.CARE
Q4 20245 Jun 2025